期刊文献+

重组人尿激酶原纯化工艺病毒去除效果验证 被引量:1

Verification of Purification Procedure of Recombinant Human Prourokinase for Virus Removal
原文传递
导出
摘要 目的验证重组人尿激酶原(Prourokinase,Pro-uk)纯化工艺的病毒去除效果。方法采用模拟Pro-uk纯化工艺中阴离子和阳离子交换层析的scale-down模型,以水泡性口炎病毒(Vesivular stomatitis virus,VSV)、脑心肌炎病毒(Encephalo-myocarditis virus,EMCV)、人单纯疱疹病毒1型(Herpes simplex virus type-1,HSV-1)为指示病毒,采用细胞病变法评价离子交换层析的病毒去除效果。结果阴离子交换层析对脂包膜病毒VSV和HSV-1的去除能力强,对无脂包膜病毒EMCV的去除能力较弱;阳离子交换层析对VSV和HSV-1的去除能力较弱,对EMCV的去除能力较强。经离子交换层析纯化后,3种指示病毒的累计去除效率均>99.99%(大于4 log10)。结论 Pro-uk纯化工艺中的离子交换层析是控制病毒安全性的有效步骤,其去除效率达到了《生物组织提取制品和真核细胞表达制品的病毒安全性评价技术审评一般原则》规定的安全标准。 Objective To verify the purification procedure of recombinant human prourokinase(Pro-uk) for virus removal.Methods The effect of viral removal by ion exchange chromatography was evaluated by scale-down model simulating the anion and cation exchange chromatography in purification procedure of Pro-uk,using esivular stomatitis virus(VSV),encephalomyocarditis virus(EMCV),herpes simplex virus type-1(HSV-1) as indicators.Results Anion exchange chromatography was effective in removal of lipid-enveloped viruses such as VSV and HSV-1,while was less effective in non-lipid-enveloped EMCV.However,cation exchange chromatography was less effective in removal of VSV and HSV-1 while was effective in EMCV.All the cumulative removal efficacies of the three kinds of indicator viruses by ion exchange chromatography were more than 99.99%(more than 4 log10).Conclusion The ion exchange chromatography step in purification procedure of Pro-uk was effective in control of safety of viruses,by which the removal efficacy of viruses met the General Requirements for Technical Evaluation on Virus Safety in Products Extracted from Organic Tissues and Expressed in Eukaryotic Cells.
出处 《中国生物制品学杂志》 CAS CSCD 2011年第6期695-698,共4页 Chinese Journal of Biologicals
关键词 重组人尿激酶原 纯化工艺 离子交换层析 病毒去除 Recombinant human prourokinase Purification procedure Ion exchange chromatography Virus removal
  • 相关文献

参考文献12

  • 1丁有学,李响,韩春梅,饶春明,王军志.重组人尿激酶原质控方法和质量标准的研究[J].中国生物制品学杂志,2007,20(7):515-518. 被引量:4
  • 2宁荣霞,王瑞,崔晓迎.新型溶栓药物重组人尿激酶原[J].中国新药杂志,2008,17(5):430-432. 被引量:19
  • 3许骥,华琦,刘力松,万云高,李东宝,胥照平,姜燕,杨旭,李天德,胡大一,刘荣坤,杨峥.重组人尿激酶原与尿激酶对急性心肌梗死患者纤溶系统影响的比较[J].首都医科大学学报,2005,26(2):132-135. 被引量:35
  • 4国家食品药品监督管理局药品审评中心.生物组织提取制品和真核细胞表达制品的病毒安全性评价技术审评一般原则[S].,2005.12.
  • 5Shi L, Chen Q, Norling LA, et al. Real time quantitative PCR as a method to evalute xenotropic marine leukemia virus removal during pharmaceutical protein purification [J]. Biotechnol Bioeng, 2004, 87 (7): 884-896.
  • 6巩薇,付瑞,王吉,卫礼,肖镜,贺争鸣.动物源性生物制品病毒灭活/去除工艺的验证[J].中国生物制品学杂志,2007,20(12):920-923. 被引量:19
  • 7Strauss DM, Gorrell J, Plancarte M, et al. Anion exchange chromatography provides a robust, predictable process to ensure viral safety of biotechnology products [J]. Biotechnol Bioeng, 2009, 102 (1): 168-175.
  • 8Sofer G. Validation: Ensuring the accuracy of scaled-down chromatography models [J]. BioPharm, 1996, 9 (9): 51-54.
  • 9Darling A. Validation of biopharmaceutical purification processes for virus clearance evaluation [J]. Mol Biotechnol, 2002, 21 ( 1 ): 57-83.
  • 10国家药典委员会 二部.中华人民共和国药典[S].北京:化学工业出版社,2005.附录.

二级参考文献27

  • 1许骥,华琦,刘力松,万云高,李东宝,胥照平,姜燕,杨旭,李天德,胡大一,刘荣坤,杨峥.重组人尿激酶原与尿激酶对急性心肌梗死患者纤溶系统影响的比较[J].首都医科大学学报,2005,26(2):132-135. 被引量:35
  • 2李振平.提高血液制品病毒安全性的途径[J].微生物学免疫学进展,1996,24(1):83-85. 被引量:1
  • 3梁峰,胡大一,吴明营,李田昌,史旭波,汤楚中,刘旭晴.重组尿激酶原治疗急性心肌梗死的疗效和安全性评价[J].中国实用内科杂志,2006,26(2):187-189. 被引量:5
  • 4陈连锋,田明,郭洪文,冮洁.溶栓剂的研究进展[J].中国生物制品学杂志,2006,19(4):426-429. 被引量:10
  • 5GRENSHAW BS, GRANGER CB, BIMBAUM Y,et al. GUSTO- 1 ( Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. Risk factors, angiographic patterns,and outcomes in patients with ventricular septal defect complicating acute myocardial infarction [ J ]. Circulation, 2000, 101 (1): 27 -32.
  • 6BELL WR. Present-day thrombolytic therapy: therapeutic agentspharmacokinetics and pharmacodynamics [J]. Rev Cardiovase Med, 2002, 3 ( Suppl 2 ) : S3d - S4d.
  • 7WU W, NARASAKI R, MAEDA F, et al. Glucosyldiacylglycerol enhances reciprocal activation of prourokinase and plasminogen [J]. Biosci Biotechnol Biochem, 2004, 68(7) : 1549 - 1556.
  • 8BAR FW, MEYER J, VERMEER F, et al. Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction [ J ]. Am J Cardial, 1997, 79 (6) : 727 - 732.
  • 9VERMEER F, BOSL I, MEYER J, et al. Saruplase is a safe and effective thrombolytic agent; observations in 1,698 patients: resuits of the PASS study. Practical Applications of Saruplase Study [J]. J Thromb Thrombolysis, 1999, 8(2):143-150.
  • 10TEBBE U, MICHELS R, ADGEY J, et al. Randomized doubleblind study comparing saruplase with streptokinase therapy in a cute myocardial infarction : the COMPASS equivalence trial[ J ]. JAm Coll Cardiol, 1998, 31(6) : 487 -493.

共引文献468

同被引文献6

  • 1国家食品药品监督管理局药品评审中心.生物组织提取制品和真核细胞表达制品的病毒安全性评价技术审评一般原则[S],2005.
  • 2王军志.生物技术药物研究开发和质量控制[M]{H}北京:科学出版社,2002.
  • 3殷震;刘景华.动物病毒学[M]北京:科学出版社,1997329-331.
  • 4Lute S,Norling L,Hanson M. Robustness of virus removal by protein A chromatography is independent of media lifetime[J].{H}Journal of Chromatography A,2008,(1-2):17-25.
  • 5巩薇,付瑞,王吉,卫礼,肖镜,贺争鸣.动物源性生物制品病毒灭活/去除工艺的验证[J].中国生物制品学杂志,2007,20(12):920-923. 被引量:19
  • 6程立均,马翠卿,杨建岭,魏敬双,张世雄,刘俊乐,魏林,贾茜.重组单抗药物亲和层析病毒去除工艺验证[J].中国生物制品学杂志,2011,24(7):842-844. 被引量:3

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部